Samjin Pharm Launches Breast Cancer Treatment Fulveserd
2h ago
Source
Seoul Economic DailySamjin Pharm Launches Breast Cancer Treatment Fulveserdsedaily.comSamjin Pharmaceutical has launched Fulveserd (fulvestrant), a SERD treatment for advanced and metastatic breast cancer, usable in both monotherapy and combination with CDK4/6 inhibitors.
You might also wanna read
AstraZeneca to pull breast cancer and endometriosis drug Zoladex from Australian market in November
AstraZeneca is removing the breast cancer and endometriosis drug Zoladex from Australia's Pharmaceutical Benefits Scheme (PBS) and private m
theguardian.com·25d ago
Breast Cancer Treatment Strategies: AI ± CDK4/6 Inhibitors, Biomarkers, and ESR1 Mutations
This article appears to be a medical education piece focused on breast cancer treatment strategies, specifically discussing patients progres
mdsc.pe·12d ago
SEZ6-targeting antibody−drug conjugate ABBV-706 in advanced small cell lung cancer and solid tumors: a phase 1 trial
doi.org·3d ago
Ask HN: What is the latest on treatment of Metastatic Breast Cancer?
news.ycombinator.com·1y ago
Trodelvy's FDA Approval Highlights Cybersecurity Risks in Healthcare Data Infrastructure
The article examines the cybersecurity vulnerabilities exposed by the FDA approval of Trodelvy (sacituzumab govitecan) for metastatic triple
undercodetesting.com·10d ago
Could Ozempic Lower Breast Cancer Risk? What to Know
ELLE·5d ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.